TickerTalks
Browse all tickers →
TickerTalks›$EVO
EVEVO

Evotec SE

$EVO·$544M·Drug Manufacturers - Specialty & Generic·Healthcare
$1.40-1.8%YTD-55.3%1Y-63.9%
Price updated 13m ago·X counts updated 5d ago
EVEVO
$EVOEvotec SE
$1.40-1.76%85 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $EVO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

85X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $EVO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 54% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data11 posts analyzed · as of 2026-09-14

Evolution AB concurrent player counts are printing new ATHs — 113k-129k peaks and repeated week-over-week gains. Anthropic-solving-an-EVO-cybersecurity-problem gossip is being framed as a fresh call-option catalyst. Charts are near ATH; no visible bear voice in the sample.

Read what X is saying about $EVO

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $EVO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyStalledAI verdict · as of 2026-10-03

The move has stalled — likely just drifts unless something new shows up.

A drug-discovery CRO at 52-week lows with a CSO transition and a shrinking top line — the setup is cheap, not fixed.

Evotec is a drug-discovery CRO serving pharma and biotech customers — the pitch is 'the picks-and-shovels of early-stage R&D.' The 2026 drawdown has been severe: shrinking revenue, deeper losses, and ongoing leadership transition without a clear operational reset.

  • The P&L is going backwards: last quarter revenue was down 20% YoY to €159M at a -35% operating margin, with trailing EPS prints missing Street estimates by 275% and 209% — this is a business reflecting both customer pullback and internal execution issues.
  • The management signal is specific: a Chief Scientific Officer transition during a drawdown period is either a sign that a reset is being prepared or that structural problems have reached the C-suite — the stock at 4% of its 52-week range and 41% below the 200-day says the market is reading it as the latter.

The Nov 5 earnings print needs to show revenue stabilization and a credible path to margin improvement. Named new biotech customers plus an operating-expense restructuring plan is the trigger for a reset; another sub-€160M revenue print at a wider margin loss confirms the stalled trajectory.

What to watch: Nov 5 Q3 earnings — revenue direction, operating margin, cash runway, and any named biotech customer wins. Revenue stabilization plus margin improvement is the trigger; another large revenue decline is the invalidation.

On the calendar: 2026-11-05 — Q3 earnings

event ahead 30dcso transition

Read the AI verdict on $EVO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

German contract drug discovery partner working across multiple disease areas with pharma and biotech companies globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $EVO.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $EVO

Partial — German contract drug discovery partner working across multiple disease areas with pharma and biotech companies globally.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-13.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-24.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
11.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.17$-0.05-275.4%
Q1 2026May 6, 2026$-0.46$-0.15-209.5%
Q1 2026Apr 8, 2026$0.05$0.21-74.0%
Q3 2025Nov 5, 2025$-0.14$-0.14-1.4%
Next earningsThu, Nov 5·consensus EPS $-0.29

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$159.2M-20.4%-1.0%-35.4%$-0.35$-6.4M
Q4 FY25$250.9M+13.4%31.0%9.6%$0.04$46.6M
Q3 FY25$163.9M-11.4%-0.0%-27.2%$-0.12$-89.0M
Q2 FY25$171.2M-6.0%5.0%-16.2%$-0.12$2.7M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$612.0M$585.8M – $687.3M-$0.66-$0.77 – -$0.624
FY27$732.2M$700.9M – $822.3M-$0.16-$0.19 – -$0.155
FY28$793.9M$760.0M – $891.6M$0.01$0.01 – $0.011
FY29$825.8M$790.5M – $927.4M$0.10$0.09 – $0.112
FY30$901.6M$863.1M – $1.0B$0.22$0.21 – $0.252

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-19.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-46.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 336.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.265-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentMay 1SC 13D/A
+ 9 other (9 6-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Boardgurufocus.com·2d agoEvotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Boardprnewswire.com·2d agoEvotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – Time to Buy?defenseworld.net·17d agoEvotec Announces Chief Scientific Officer Transitiongurufocus.com·18d agoEvotec Announces Chief Scientific Officer Transitionprnewswire.com·18d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$PCRX$TEVA$ACB$ZTS$ZYBT$ELAN$INDV$EBS
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport